TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

RHOFADE

OXYMETAZOLINE HYDROCHLORIDE
Dermatology Approved 2017-01-18
1
Indication
--
Phase 3 Trials
9
Years on Market

Details

Status
Prescription
First Approved
2017-01-18
Routes
TOPICAL
Dosage Forms
CREAM

Companies

Active Ingredient: OXYMETAZOLINE HYDROCHLORIDE

RHOFADE Approval History

Loading approval history...

What RHOFADE Treats

2 indications

RHOFADE is approved for 2 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Rosacea
  • Facial Erythema
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

RHOFADE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

RHOFADE ® (oxymetazoline hydrochloride) cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. Rhofade cream is an alpha 1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.

RHOFADE Patents & Exclusivity

Latest Patent: Jun 2035

Patents (7 active)

US9974773 Expires Jun 11, 2035
US10751325 Expires Jun 11, 2035
US12350255 Expires Jun 11, 2035
US10335391 Expires Jun 11, 2035
US11517560 Expires Jun 11, 2035
US8883838 Expires Dec 1, 2031
US7812049 Expires May 2, 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.